Psychiatric Times

🎙️🧬 This week's "Brain Trust" episode is now live! Guest and Psychiatric Times Editor in Chief, John J. Miller, MD, explores pharmacogenetic testing in psychiatry: psychiatrictimes.com/view/podcast-p…

According to a new systematic review and meta-analysis, there is no causal link between the use of nearly all antidepressants during pregnancy and an increased risk of autism/ADHD. psychiatrictimes.com/view/antidepre…

Our Schizophrenia Special Report starts releasing today. Read the introduction by Special Report Chair Peter F. Buckley, MD, now: psychiatrictimes.com/view/understan…

An estimated 77,000 individuals with psychotic disorders are in US jails and prisons at any given time. This could, in part, be driven by the neurological deficit anosognosia, in which an affected individual is unable to perceive their own illness. psychiatrictimes.com/view/anosognos…

What does cannabis legalization mean for psychosis risk? psychiatrictimes.com/view/cannabis-…

Should we create a new term for borderline personality disorder? Renaming borderline personality disorder fails to address the condition's complexity. psychiatrictimes.com/view/borderlin…

Join us July 10–11 in Huntington Beach for the Southern California Psychiatry Conference. Explore emerging therapies, real-world case discussions, and expert insights on MDD, SUD, schizophrenia, and more. Register now: hubs.li/Q04g9drT0

A large meta-analysis found that GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity. Read the research here: psychiatrictimes.com/view/evaluatin…

The HHS is targeting psychiatric overprescribing. Joseph F. Goldberg, MD, urges careful deprescribing: stop ineffective medications and replace them with evidence-based treatments. psychiatrictimes.com/view/what-clin…

The May issue of Psychiatric Times is now live! This month, we take closer look at the psychopharmacology pipeline. Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6…

The FDA has cleared @NRxPharma to initiate a clinical trial of NRX-101 vs placebo in patients with depression and suicidality who are being treated with either robotic-assisted or sham TMS. psychiatrictimes.com/view/fda-clear…

💊 🧠 Our May cover story by Editor in Chief John J. Miller, M.D. is now live! Read about the psychopharmacology pipeline and the potential treatments you need to have your eyes on here: psychiatrictimes.com/view/psychiatr…

The HHS has rolled out a plan to curb psychiatric overprescribing, pushing deprescribing guidance while major psychiatric organizations like the @APApsychiatric and @afspnational urge caution and access to care. psychiatrictimes.com/view/hhs-launc…

"Brain Trust: Conversations in Psychopharmacology" is now available on Apple Music, Spotify, and PsychiatricTimes.com! Tune in for discussions on the most important and interesting topics in psychiatric pharmacology and clinical practice: psychiatrictimes.com/series/brain-t…

Thalia Robakis, MD, PhD, discusses the randomized clinical trial happening at Mount Sinai, examining the efficacy and tolerability of the SAINT transcranial magnetic stimulation (TMS) protocol in women with postpartum depression. @PsychTimes psychiatrictimes.com/view/the-saint…

According to new network meta-analysis findings, lumateperone (Caplyta) ranked highest across 4 key efficacy measures and demonstrated a favorable tolerability profile, particularly with respect to weight, when compared with the other agents evaluated. psychiatrictimes.com/view/lumateper…

ICYMI: Auvelity for the treatment of Alzheimer disease dementia is now FDA approved. Read the news here ⬇️

Learn about unmet needs in effectively treating patients with MDD, and explore the latest research in digital therapeutics for depression symptoms. Watch now: bit.ly/48wGdkX #Sponsored

New survey data from the @SczPolicyAction show that despite growing recognition of serious mental illness as a treatable medical condition, access to consistent, evidence-based care remains limited. psychiatrictimes.com/view/new-span-…

Our May theme: Psychedelics. We want to hear your clinical insights! Submit to our content series ⬇️ psychiatrictimes.com/view/presentin…